Alvotech's board of directors approves plan to prepare for listing on nasdaq main market in iceland

Alvotech (nasdaq: alvo), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its board of directors has approved a plan to move its share listing from the first north growth market to the nasdaq main market in iceland (“main market”). alvotech's admission to trading on the main market is subject to an extensive application process. a main market listing can increase a company's visibility and may result in inclusion in icelandic and international indexes. starting in september 2022, shares of companies listed on the icelandic main market may become eligible for the ftse global all cap and related indexes, subject to meeting certain conditions with respect to trading volume and duration of listing. the selection of shares to be included in the ftse indexes is revised periodically, every six months.
ALVO Ratings Summary
ALVO Quant Ranking